Protocol #0207-545: a phase I/II, escalating dose, open-label evaluation of safety, feasibility, and tolerability of transgenic lymphocyte immunization (TLI) vaccine subjects with histologically proven prostate adenocarcinoma.

Human gene therapy

Volumn 14, Issue 3, 2003, Pages 301-302

  Zanetti, Mauricio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

ARTICLE; CARCINOMA; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE HYPERTROPHY;

ANTINEOPLASTIC PROTOCOLS; CANCER VACCINES; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 0141672265     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)